Vesalius Longevity Labs Inc. — SEC Form D Filing
Vesalius Longevity Labs Inc. filed an SEC Form D on November 3, 2026, reporting $30.11M raised in Pharmaceuticals.
Form D filing details
- Filing
- SEC Form D
- Filing date
- November 3, 2026
- Amount reported
- $30.11M
- Round stage
- Growth stage, driven by a $30.1 million equity raise and a planned public listing via a reverse-takeover transaction.
- Industry
- Pharmaceuticals
- Website
- https://www.vesaliustx.com
What the company does
Securities: Equity. Exemption: Rule 506(b). Incorporated: BRITISH COLUMBIA, CANADA
Problem
Healthcare providers and longevity clinics lack standardized access to high-quality peptide active pharmaceutical ingredients and integrated fulfillment infrastructure needed to scale preventive therapeutics.
Solution
Vesalius Longevity Labs delivers the Peptual active pharmaceutical ingredient platform alongside turnkey telehealth software and product fulfillment to enable clinics to administer advanced longevity therapeutics.
Why now
Rapidly growing consumer demand for proactive healthspan optimization combined with advancements in peptide synthesis necessitates compliant supply chains and provider enablement technologies.
Source: SEC EDGAR Form D filing